Catalog No.S3956 Synonyms: ligustrazine
Molecular Weight(MW): 136.19
Tetramethylpyrazine (ligustrazine, TMP) is a natural compound isolated from Chinese herbal medicine Ligusticum wallichii (Chuan Xiong) with anti-inflammation, antioxidant, antiplatelet, and antiapoptosis activities.
Purity & Quality Control
Choose Selective Immunology & Inflammation related Inhibitors
|Description||Tetramethylpyrazine (ligustrazine, TMP) is a natural compound isolated from Chinese herbal medicine Ligusticum wallichii (Chuan Xiong) with anti-inflammation, antioxidant, antiplatelet, and antiapoptosis activities.|
Tetramethylpyrazine (TMP) is described as "calcium antagonist" and produces a vasodilation effect via inhibiting Ca2+ influx and the release of intracellular Ca2+ at first. TMP could restrain mitochondrial ROS generation and upregulate the expression of PGC1, NRF1, and Tfam, which reflects mitochondrial biogenesis. TMP also exerts an endothelium protective property via downregulating the expression of ICAM-1 and HSP60. TMP can exert antiapoptosis ability by inhibiting macrophage COX-2. TMP can restrain LPS-induced IL-8 overexpression in HUVECs at both the protein and mRNA levels, which is possibly due to blocking the activation of the NF-kB-dependent pathway; the involvement of ERK and p38 MAPK signaling pathway has also been observed.
|In vivo||Akt and the endothelial isoform of nitric oxide synthase (eNOS) phosphorylation are significantly upregulated after Tetramethylpyrazine (TMP) pretreatment in vivo. TMP can suppress the proliferation of VSMC in rabbit aortic vascular. TMP can decrease the ANP mRNA expression in cardiomyocyte hypertrophy rat model and suppress the level of pJAK2, pJAK1, or pSTAT3, demonstrating that TMP can inhibit JAK-STAT signal transduction. TMP is reported to possess a broad spectrum of pharmacological effects, such as antioxidant, anti-inflammatory, antifibrosis effects. Early pharmacokinetic research has determined the metabolism rate of TMP and verified its in-vivo short half-life of T1/2=2.89 h. TMP is found to protect ischemic brain damage, and promote cell proliferation and differentiation stimulated by ischemia.|
|In vitro||DMSO||27 mg/mL (198.25 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03993821||Not yet recruiting||Drug: Burosumab||Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS)|Epidermal Nevus Syndrome||Laura Tosi|Children''s Research Institute|Ultragenyx Pharmaceutical Inc||August 2019||Early Phase 1|
|NCT03748966||Recruiting||Drug: Calcitriol||X-linked Hypophosphatemia|Hypophosphatemic Rickets|Hypophosphatemic Rickets X-Linked Dominant||Massachusetts General Hospital|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||March 28 2019||Early Phase 1|
|NCT03920072||Recruiting||Drug: Burosumab||X-linked Hypophosphatemia||Kyowa Kirin Pharmaceutical Development Ltd||March 7 2019||Phase 3|
|NCT03797729||Not yet recruiting||Drug: Tirofiban|Drug: Normal saline||ST Elevation Myocardial Infarction||Shanghai Zhongshan Hospital||February 2019||Phase 4|
|NCT03424525||Recruiting||Drug: 11C-Trimethoprim||Bacterial Infections||University of Pennsylvania||February 1 2018||Phase 1|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.